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Abstract
Background The effect of vitamin D supplementation on postural muscles of the trunk is of particular interest because low
25-hydroxyvitamin D [25(OH) D] levels are associated with decreased postural balance and increased risk of falls. Understand-
ing the role of vitamin D supplementation plays in trunk muscle function of older adults is necessary, as this is a potentially
modiﬁable factor to improve postural muscle function and decrease the risk of falling of older adults. The objective of this
randomized controlled trial was to evaluate the effect of 12 months of vitamin D supplementation compared with placebo,
on morphology and function of the trunk muscles of adults aged 50 to 79 years with low serum 25(OH) D levels.
Methods This was a secondary analysis of a randomized, placebo-controlled, and double-blind clinical trial conducted be-
tween June 2010 and December 2013 in Tasmania, Australia. The clinical trial was registered with the Australian New
Zealand clinical trial registration agency, ClinicalTrials.gov identiﬁer: NCT01176344; Australian New Zealand Clinical Trials Reg-
istry: ACTRN 12610000495022. Participants were aged 50–79 years with ongoing symptoms of knee osteoarthritis and with
low serum [25(OH) D] (12.5 to 60 nmol/L, 5.2 to 24 ng/mL). Participants were randomly assigned to either monthly
50 000 IU oral vitamin D3 (n = 104) or an identical placebo (n = 113) for 24 months as per clinical trial protocol. The primary
outcomes in this pre-speciﬁed secondary analysis were between-group differences in change in size of rectus abdominis,
transversus abdominis, internal oblique, external oblique, and lumbar multiﬁdus muscles and function (assessed by change
in thickness on contraction) of these muscles (excepting rectus abdominis) from baseline to 12 months. Muscle size was
assessed using ultrasound imaging.
Results Of 217 participants (mean age 63 years, 48% women), 186 (85.7%) completed the study. There were no signiﬁcant
between-group differences in change in size or function of the abdominal or multiﬁdus muscles after 12 months of vitamin D
supplementation.
Conclusions A monthly dose of 50 000 IU of vitamin D3 alone for 12 months does not affect the size or ability to contract
trunk muscles of independent community-dwelling older adults with symptomatic knee osteoarthritis and low serum 25(OH) D
levels regardless of body mass index status or degree of vitamin D deﬁciency. An effect of vitamin D supplementation on other
aspects of trunk muscle function such as strength, power, or physical function cannot be ruled out.
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Introduction
Population levels of serum 25-hydroxyvitamin D [25(OH) D]
are variable around the world, but deﬁciency is common in
older adults due to decreased sun exposure, decreased pro-
duction of vitamin D in the skin, insufﬁcient intake of vitamin
D in their diet, and institutionalization.1–4 Mean population
25(OH) D levels commonly fall below 50 nmol/L (20 ng/mL),
which is considered to be the minimum target level for
adequate bone health, mineral homeostasis, and muscle
function.4–6
Common clinical presentations of severe vitamin D
deﬁciency include bone pain, gait disturbances, and muscle
weakness, especially of proximal muscles of the upper and
lower limbs and muscles of the trunk.7 Previous research
has found that vitamin D plays a vital role in muscle develop-
ment and growth.8 The mechanism may be through
1,25(OH)2 binding to a speciﬁc vitamin D receptor found in
skeletal muscle9,10 leading to de novo protein synthesis and
thus muscle cell proliferation and growth.11,12 Furthermore,
a review of randomized controlled trials (RCTs) has examined
the effect of vitamin D supplementation on several aspects of
muscle function including lower limb strength, handgrip, pos-
tural balance, gait speed, and physical performance (timed-
up-and-go test).13 Even though evidence in this review was
conﬂicting, 7 of 11 studies demonstrated beneﬁcial effects,
as has another published RCT.14 A more recent systematic
review and meta-analysis of 30 RCTs by Beaudart et al.15
found small but signiﬁcant positive effects of vitamin D sup-
plementation on lower limb muscle strength, although there
were no effects on muscle mass or power. Thus, there is both
a biological basis and clinical trial evidence for considering
that correcting vitamin D deﬁciency may improve muscle
strength and function.
Muscles of the trunk, particularly the abdominal and lum-
bar multiﬁdus muscles (MF), are postural muscles tonically
active during daily upright activities16 and essential for the
stability of the spine, balance, and posture.17–19 Trunk muscle
size is correlated with strength,20,21 and among older adults,
trunk muscle strength has been found to be associated with
mobility and falls.22,23 The effect of vitamin D supplementa-
tion on muscles of the trunk is of particular interest because
low 25(OH) D levels are associated with decreased postural
balance13 and increased risk of falls in older adults.24 Conse-
quently, vitamin D supplementation has the potential to be a
relatively cheap intervention to improve postural muscle
function and decrease the risk of falling among older adults.
Despite this, to our knowledge, the effects of vitamin D
supplementation on trunk muscles have not been assessed
previously. Therefore, the objective of this RCT was to evalu-
ate the effect of 12 months of vitamin D supplementation
compared with placebo, on morphology and function of the
trunk muscles of adults aged 50 to 79 years with low serum
25(OH) D levels.
Methods
Trial design
The Vitamin D Effect on Osteoarthritis (VIDEO) study was a
randomized, placebo-controlled, and double-blind clinical
trial conducted between June 2010 and December 2013, with
the main objectives of determining if vitamin D supplementa-
tion could reduce knee cartilage volume loss, prevent
progression of knee structural abnormalities, improve lower
limb muscle strength, and alter the progression of knee
pain.25,26 The protocol for VIDEO and its pre-speciﬁed
analyses have been published.25 This pre-speciﬁed secondary
analysis investigating the effects of vitamin D supplementa-
tion on the size of abdominal and lumbar MF muscles over
12 months was undertaken in one of the two VIDEO sites,
namely, Hobart, Tasmania, Australia. VIDEO was registered
with the Australian New Zealand clinical trial registration
agency, ClinicalTrials.gov identiﬁer: NCT01176344; Australian
New Zealand Clinical Trials Registry: ACTRN
12610000495022.25 The clinical trial and sub-studies were
conducted following the Note for Guidance on Good Clinical
Practice (CPMP/ICH/135/95) and the 2007 Australian
National Statement on Ethical Conduct in Human Research.
Participants
Participants were recruited through advertisements in the
local media and community groups, and referrals from
general practitioners, specialist rheumatologists, and ortho-
paedic surgeons. Inclusion and exclusion criteria are
described in detail in the published clinical trial protocol.25
In brief, participants were people aged 50–79 years, with on-
going symptoms of knee osteoarthritis for at least 6 months
with pain levels between 20 and 80 mm on a 100 mm visual
analogue scale and serum 25(OH) D levels between 12.5 and
60 nmol/L (5.2 to 24 ng/mL). Exclusion criteria included
severe radiographic knee osteoarthritis, severe pain on stand-
ing, hypersensitivity to vitamin D, any condition affecting oral
drug absorption, and anticipated need for knee or hip surgery
within the next 2 years. Ethics approval was received from
The Tasmania Health and Human Ethics Committee
(reference number H1040). Written informed consent was
obtained from all participants.
Randomization and blinding
Participants were randomly assigned to a vitamin D or a
placebo group using computer-generated allocation with a
1:1 ratio. Allocation concealment was ensured by using a
central automated process independent of the investigators.
Participants, investigators, and research coordinators were
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all blinded to the treatment allocation. Blinding both for the
main study and for the trunk muscle outcomes was main-
tained until all data were collected, cleaned, and conﬁrmed
for accuracy and statistical analyses were completed.
Interventions
Participants in the treatment group were given one 50 000 IU
(1.25 mg) vitamin D3 (cholecalciferol) capsule per month, for
24 months. Participants in the control group were given an
identical inert placebo. The vitamin D3 compound and inert
placebo were acquired from Nationwide Compounding
Pharmacy, Melbourne, Australia.25
Outcomes
Primary outcome measures in this pre-speciﬁed secondary
analysis were between-group differences in change in muscle
morphology: (i) changes in muscle thickness of the abdominal
muscles [rectus abdominis (RA), transversus abdominis (TrA),
internal oblique, and external oblique] and the lumbar MF
muscles; (ii) changes in cross sectional area (CSA) of the MF
muscles; and (iii) changes in muscle thickness with contrac-
tion of the abdominal muscles (except RA) and the MF
muscles from baseline to 12 months.
Image capture and measurement
Ultrasound muscle images were taken using a Phillips HDI
5000 ultrasound machine (Bothwell, WA, USA) in brightness
mode (B-mode) with a handheld 4–7 MHz broadband curved
array transducer. Image capture and measurement of the
abdominal wall and MF muscles were undertaken following
previously published protocols.27–36 The ultrasound imaging
(USI) assessments were conducted by a physical therapist
who undertook 36 h of practical training in USI at the begin-
ning of the project.
Muscles of the abdominal wall were imaged in transverse
section. Participants were positioned in supine lying, with a
pillow under their knees.30,28 To elicit a voluntary contraction
of the abdominal wall, participants were asked to ‘take a re-
laxed breath in and out, hold your breath out, and then draw
in your lower abdomen without moving your spine’.28 The RA
muscles were only imaged at rest, and the transversus
abdominis, internal oblique, and external oblique muscles
were imaged at rest and on contraction.30
Imaging of the lumbar MF muscles was performed with
participants positioned in prone lying, with a pillow placed
under their abdomen to reduce lumbar lordosis.31,32,34
Images of the lumbar MF muscles were captured both at rest
(in the transverse plane) and during contraction (in the
parasagittal plane). Instructions for the isometric contraction
were ‘take a relaxed breath in and out, hold your breath out
and try to slowly “swell” and contract the muscle without
moving the spine’.37
Ultrasound images were stored and later analysed ofﬂine
by a single examiner using a software package (Image J Image
Processing and Analysis, version IJ 1.46r, http://imagej.nih.
gov/ij/). The thickness of the abdominal muscles was mea-
sured as the perpendicular distance between the superior
and inferior hyperechoic muscle fascias at approximately
the middle of the image identiﬁed using the software’s
Cartesian coordinates.28 The CSA of the MF muscle was
measured by tracing around the inner edge of the fascial
boundaries of the muscle,27,31 and the thickness of the MF
muscle was measured from the tip of the zygapophyseal joint
to the inferior fascial edge of the superior border of the mus-
cle.34 Intraclass correlation coefﬁcients (ICC) for abdominal
and MF muscle measurements were ICC = > 0.85 for
interrater USI image measurement reliability35 and
ICC = 0.74–0.98 for test–retest reliability.36
Other factors
Height was measured by stadiometer to the nearest 0.1 cm
(Leicester Height Measure, Invicta Plastics Ltd, Leicester,
UK). Weight was measured by calibrated scales (Heine
S-7307, Heine, New Hampshire, USA) and body mass index
(BMI) was calculated [weight (kg)/height (m2)]. Knee pain
scores were obtained using a visual analogue pain scale in
100 mm, assessing pain during walking, using stairs, in
bed, sitting or lying, and standing. The total pain score
was calculated as the sum of the ﬁve items (range
0–500).38 Total Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) score was calculated as the
sum of the scores in each of its subscales that included pain,
stiffness, and physical function. Missing data were managed
according to the WOMAC user guide.38 Physical activity was
measured using the short version of the International
Physical Activity Questionnaire (IPAQ) instrument. Data
were collected on vigorous and moderate activity as well
as walking and sitting, but data on sitting were not used
in the analysis. Total IPAQ scores were calculated according
to published guidelines.39,40 Current low back pain status
was assessed by a questionnaire asking ‘do you currently
have any pain in your back?’, and pain scores were obtained
using a Visual Analogue Scale (0–100 mm). History of back
surgery, abdominal surgery, and medications were obtained
by questionnaire. Leg strength measures to the nearest
kilogram were obtained for both legs simultaneously using
a dynamometer (TTM Muscular Meter, Tokyo, Japan) as
described by Scott et al.41 This is an isometric strength
muscle test, predominantly for the quadriceps and hip
extensor muscles. Grip strength was assessed with a
Hydraulic hand-held dynamometer.
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25-Hydroxyvitamin D
Serum 25(OH) D was assayed at screening, 3 and 24 months.
Blood samples were centrifuged after standing for 10 min at
room temperature and the resultant serum frozen at 80°C
until assayed using direct competitive chemiluminescent
immunoassays (DiaSorin Inc.). The intraassay and interassay
coefﬁcients of variation were 3.2% and 6.0%.26
Sample size
Calculations were based on the standard deviations reported
by Rankin et al.30 for the thickness of the abdominal muscles
and by Wallwork et al.42 for thickness and CSA of the lumbar
multiﬁdus. Correlations between measurements and remea-
surement of r = 0.9 for abdominal muscle thickness, r = 0.5
for multiﬁdus thickness, and r = 0.7 for multiﬁdus CSA were
observed in our reliability study.36 On that basis, this study
of projected size 200 subjects (100 in each arm) would have
80% power to detect between-group differences of 0.02 to
0.05 cm for change in abdominal muscle thickness, 0.20
to 0.21 cm for change in multiﬁdus thickness, and 0.28 to
0.40 cm2 for change in multiﬁdus CSA.
Statistical analysis
As summary measures of their distributions, means and
standard deviations were used for continuous measures, and
percentages and frequencies were used for categorical fac-
tors. Random intercept linear mixed models were used to es-
timate the change between baseline and follow-up in both
treatment arms, and the difference in change for the treat-
ment groups, in this intention-to-treat analysis. Themodels in-
cluded binary terms for side (left or right) in measurements of
muscle thickness and CSA and for state (relaxed or contracted)
of muscle thickness. Changes in muscle morphology, that is
thickness and CSA in the relaxed state, and change in function
(assessed by changes inmuscle thickness on contraction) were
compared for each group of participants. Because there was
no statistically signiﬁcant differences between the two sides
for either group, the means of the right and left muscle sizes
were used in the analysis. In additional analyses, adjustments
were made for age, sex, and BMI (pre-speciﬁed in the proto-
col) and for additional factors that were potential confounders
and for which there was an imbalance between the treatment
arms. Only the adjustment for lower limb strength resulted in
a marked change in the estimated effect of the intervention
(Table 1). To test for interaction by serum 25(OH) D status at
baseline, a binary term generated using a serum 25(OH) D
cut-point of 25 nmol/L (10 ng/mL) was included as a covariate
and as a component of a product term in the regression
model. Similarly, testing for interaction by BMI category
[normal (≤25 kg/m2), overweight (>25 to <30 kg/m2), and
obese (≥30 kg/m2)] was performed. The step-down procedure
of Holm43 was used to control the family-wise error rate
(Table 3). Statistical analyses were performed using Stata
(Version 14.0, Stata Corporation, TX, USA), and a two-sided
P-value of 0.05 was deemed statistical signiﬁcance.
Table 1 Baseline characteristics of vitamin D and placebo groups
Vitamin D (N = 104) Placebo (N = 113)
Male sex: % (n/N) 53 (55/104) 51 (58/113)
Age (years) 63.7 (7.4) 63.0 (7.3)
Weight (kg) 84.4 (15.5) 84.4 (15.1)
Height (cm) 169.1 (10.2) 170.0 (9.7)
BMI (kg/m2) 29.5 (5.3) 29.5 (4.5)
BMI ≤25 kg/m2: % (n/N) 15 (16/104) 11 (12/113)
BMI >25 to <30 kg/m2: % (n/N) 47 (49/104) 43 (49/113)
BMI ≥30 kg/m2: % (n/N) 38 (39/104) 46 (52/113)
25-hydroxyvitamin D (nmol/L) 42.5 (12.0) 43.9 (12.1)
Total knee WOMAC score (0–2400) 576.3 (394.9) 571.7 (373.3)
Pain (0–500) 121.3 (88.3) 122.7 (84.5)
Stiffness (0–200) 52.6 (41.9) 58.1 (40.5)
Function (0–1700) 402.4 (287.0) 390.9 (274.7)
Physical activity—IPAQ score 3628.9 (4762.0) 3057.6 (3054.0)
Current low back pain: % (n/N) 39 (41/104) 34 (38/113)
Current low back pain—VAS score 28.0 (19.3) 28.3 (22.0)
History of low back surgery: % (n/N) 6 (6/104) 11.0 (12/113)
History of abdominal surgery: % (n/N) 55 (57/104) 50 (56/113)
Medication: Statins; % (n/N) 6.7 (7/104) 12.0 (13/113)
Lower limb strength (kg) 67.1 (42.9) 70.0 (44.8)
Grip strength: right (kg) 30.7 (12.3) 30.8 (11.0)
Grip strength: left (kg) 29.7 (12.0) 29.7 (11.1)
All results reported mean (standard deviation) or % (n/N) where indicated. BMI, body mass index; IPAQ, International Physical Activity
Questionnaire (MET-min/week); VAS, visual analogue scale (0–100 where 0 = no pain and 100 = very worst pain); WOMAC, Western On-
tario and McMaster Universities Osteoarthritis Index.
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Results
Of the 422 potential VIDEO participants screened at the
Hobart site, 265 were randomized and assigned to the
treatment or placebo groups. Of these, 104 participants in
the treatment group (39.3%) and 113 participants in the
placebo group (42.6%) had images of their trunk muscles
taken at baseline for this sub-study. Ninety-ﬁve and 91
participants had trunk muscle images taken at follow-up
1 year later in the treatment and placebo groups, respec-
tively (Figure 1).
Table 1 summarizes the baseline characteristics of partici-
pants in the treatment and placebo groups in this sub-study.
The groups were reasonably well matched, with some
difference in proportions for gender, low back pain, history
of abdominal surgery, statins use, and lower limb strength.
Figure 1 Flowchart of participation.
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Overall knee pain scores measured by the WOMAC were in
the low ranges (122/500), while physical activity levels
measured by the IPAQ were in the higher ranges
(>3000 MET-min/week).40 Mean serum 25(OH) D levels in
the vitamin D group increased by 39.3 nmol/L (15.6 ng/
mL) and 44.5 nmol/L (18.0 ng/mL) at 3 and 24 months
respectively, compared with an initial increase of
17.6 nmol/L (7.2 ng/mL) at 3 months and a total increase
of 6.8 nmol/L (2.8 ng/mL) at 24 months in the placebo
group. There were no baseline differences between the
participants in this sub-study and the entire VIDEO cohort
(n = 413).26 The BMI of the study population was relatively
high (over 85% were overweight or obese). In the 172
participants of this USI sub-study who had serum 25(OH)
D measured at 24 months, increase in serum 25(OH) D
levels from baseline to 24 months in overweight (>25 to
<30 kg/m2) and obese participants (≥30 kg/m2) was
8.7 nmol/L (3.6 ng/mL) and 5.2 nmol/L (2.0 ng/mL) lower,
than those participants with normal BMI (≤25 kg/m2). In
fact, 76% of the treatment group achieved serum 25(OH)
D levels ≥75 nmol/L (≥30 ng/mL) by 24 months compared
with only 7% of the placebo group, the former including
25/33 (76%) of obese and 22/33 (67%) of overweight treat-
ment arm participants.
The between-group treatment effects for trunk muscle size
and change in thickness with contraction were small (less
than 4% in each muscle), inconsistent in direction, and not
statistically signiﬁcant (Tables 2 and 3). Adjusting for age,
sex, and BMI did not change these results (Tables 4 and 5).
While additional adjustment for leg strength increased the ef-
fect size for multiﬁdus thickness at the L2/L3, L3/L4, and
L4/L5 vertebral levels, the only between-group difference
that was statistically signiﬁcant after controlling for family-
wise error was at the L2/L3 vertebral level and the effect
size (3.5%) remained small (Table 5). Results were similar
after further adjustments for statin use, current low back
pain, and history of abdominal or back surgery. There were
not signiﬁcant within-group differences in trunk muscle size
or function over 12 months in either group. There were no
interactions between treatment effect and either baseline
25(OH) D status or BMI in adjusted analyses for any muscle
measure (all P < 0.05).
Adverse events
A description of adverse events for the full clinical trial has
been reported previously.26 In this sub-study, 44 (42%) out
Table 2 Changes in relaxed abdominal muscle thickness (cm) and in change in muscle thickness with contraction from baseline to follow-up by inter-
vention group
Vitamin D group Placebo Group Between-group
differences in
changeMuscle Baseline Follow-up Change Baseline Follow-up Change
RA 0.827 (0.019) 0.845 (0.019) 0.017 (0.008) 0.850 (0.018) 0.860 (0.018) 0.010 (0.008) 0.007 (0.011)
TrA (relaxed) 0.380 (0.011) 0.390 (0.012) 0.011 (0.007) 0.409 (0.011) 0.427 (0.011) 0.018 (0.007) 0.007 (0.010)
TrAa 0.168 (0.009) 0.187 (0.009) 0.018 (0.008)* 0.153 (0.008) 0.176 (0.009) 0.023 (0.009)* 0.005 (0.012)
IO (relaxed) 0.775 (0.024) 0.752 (0.025) 0.023 (0.015) 0.851 (0.023) 0.845 (0.024) 0.006 (0.015) 0.017 (0.021)
IOa 0.221 (0.019) 0.243 (0.019) 0.015 (0.016) 0.203 (0.018) 0.243 (0.019) 0.039 (0.016)* 0.024 (0.022)
EO (relaxed) 0.431 (0.013) 0.432 (0.013) 0.001 (0.008) 0.451 (0.012) 0.462 (0.013) 0.011 (0.008) 0.010 (0.011)
EOa 0.075 (0.009) 0.091 (0.010) 0.016 (0.010) 0.085 (0.009) 0.093 (0.010) 0.009 (0.010) 0.007 (0.014)
All measures are in cm and are reported as mean (standard error). EO, external oblique; IO, internal oblique; RA, rectus abdominis; TrA,
transversus abdominis.
aAbsolute change in muscle thickness with contraction, calculated as (thickness when contracted – thickness when relaxed).
*Statistically signiﬁcant P < 0.05
Table 3 Between-group differences in changes in relaxed abdominal muscle thickness (cm) and in change in muscle thickness with contraction from
baseline to follow-up with and without adjustment for relevant factors
Adjusted for
Muscle Unadjusted model Age + Sex + BMI Age + Sex + BMI + Leg strength
RA 0.007 (0.015, 0.029) 0.010 (0.012, 0.032) 0.009 (0.015, 0.032)
TrA (relaxed) 0.007 (0.027, 0.013) 0.004 (0.024, 0.016) 0.007 (0.029, 0.014)
TrAa 0.005 (0.028, 0.019) 0.004 (0.028, 0.019) 0.004 (0.030, 0.021)
IO (relaxed) 0.017 (0.058, 0.024) 0.013 (0.054, 0.028) 0.010 (0.054, 0.034)
IOa 0.024 (0.068, 0.020) 0.022 (0.066, 0.022) 0.021 (0.069, 0.026)
EO (relaxed) 0.010 (0.032, 0.126) 0.008 (0.030, 0.015) 0.010 (0.034, 0.013)
EOa 0.007 (0.019, 0.034) 0.006 (0.021, 0.034) 0.011 (0.017, 0.040)
All measures are in cm and are reported as mean (conﬁdent interval). EO, external oblique; IO, internal oblique; RA, rectus abdominis; TrA,
transversus abdominis.
aAbsolute change in muscle thickness with contraction calculated as (thickness when contracted – thickness when relaxed).
*Statistically signiﬁcant P < 0.05.
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of 104 participants in the vitamin D group reported adverse
events compared with 30 (27%) out of 113 participants in
the placebo group (Table 6). Two cases of hypercalcaemia
were reported in each group. One instance of hyperthyroid-
ism and two episodes of renal calculus were reported in the
vitamin D group.26
Discussion
To our knowledge, this is the ﬁrst RCT investigating the
effect of vitamin D supplementation on the morphology of
key postural trunk muscles of older adults. Apart from the
thickness of the MF muscles at the L2–L3 vertebral level,
there were no statistically signiﬁcant differences in change
in muscle thickness or CSA between the vitamin D and
placebo groups, and all effect sizes were small and not
clinically signiﬁcant. The results suggest that vitamin D sup-
plementation alone is not an effective means to improve
or maintain trunk muscle size over time for adults aged
50–79 years, even for those individuals with moderate to
severe deﬁciency.
The purpose of this study was to determine whether
vitamin D supplementation alone had beneﬁcial effects in
maintaining or improving trunk muscle size and function. In
the present study, the within-group changes in trunk muscle
size and function over time were all very small. Despite there
Table 4 Changes in relaxed multiﬁdus muscle thickness (cm), changes in muscle thickness with contraction, and in changes cross sectional area (cm2)
from baseline to follow-up by intervention group
Vitamin D group Placebo group Between-group
differences
in changeMuscle Baseline Follow-up Change Baseline Follow-up Change
Muscle thickness
L2/L3_MF (relaxed) 2.646 (0.046) 2.649 (0.047) 0.003 (0.043) 2.670 (0.044) 2.580 (0.047) 0.090 (0.043) 0.092 (0.060)
L2/L3_MFa 0.140 (0.018) 0.115 (0.018) 0.025 (0.019) 0.167 (0.017) 0.142 (0.018) 0.025 (0.019) 0.000 (0.026)
L3/L4_MF (relaxed) 2.331 (0.043) 2.428 (0.044) 0.097 (0.036)* 2.339 (0.041) 2.409 (0.043) 0.070 (0.036) 0.027 (0.051)
L3/L4_a 0.134 (0.018) 0.129 (0.018) 0.005 (0.021) 0.145 (0.017) 0.124 (0.018) 0.020 (0.021) 0.015 (0.029)
L4/L5_MF (relaxed) 2.864 (0.048) 2.817 (0.049) 0.047 (0.045) 2.913 (0.046) 2.842 (0.049) 0.071 (0.046) 0.024 (0.064)
L4/L5_MFa 0.168 (0.018) 0.160 (0.019) 0.008 (0.019) 0.184 (0.018) 0.180 (0.019) 0.005 (0.019) 0.003 (0.027)
L5/S1_MF (relaxed) 2.744 (0.049) 2.863 (0.051) 0.119 (0.044)* 2.758 (0.047) 2.925 (0.050) 0.167 (0.045)* 0.048 (0.063)
L5/S1_MFa 0.138 (0.019) 0.153 (0.020) 0.015 (0.021) 0.170 (0.018) 0.178 (0.020) 0.008 (0.021) 0.007 (0.030)
Cross sectional area
L2_MF_CSA 2.670 (0.054) 2.858 (0.055) 0.188 (0.027) 2.654 (0.052) 2.908 (0.053) 0.254 (0.027) 0.066 (0.038)
L3_MF_CSA 3.500 (0.061) 3.830 (0.062) 0.330 (0.037) 3.423 (0.058) 3.774 (0.060) 0.350 (0.038) 0.021 (0.053)
L4_MF_CSA 4.416 (0.068) 4.831 (0.069) 0.415 (0.038) 4.230 (0.065) 4.708 (0.067) 0.478 (0.039) 0.063 (0.054)
L5_MF_CSA 5.211 (0.081) 5.519 (0.082) 0.307 (0.048) 4.979 (0.077) 5.399 (0.080) 0.420 (0.049) 0.112 (0.068)
All measures are in cm and are reported as mean (standard error). CSA, cross sectional area; MF, multiﬁdus muscle.
aAbsolute change in muscle thickness with contraction calculated as (thickness when contracted – thickness when relaxed).
*Statistically signiﬁcant P < 0.05.
Table 5 Between-group differences in change in relaxed multiﬁdus muscle thickness (cm) and in change in muscle thickness with contraction and
cross sectional area (cm2) from baseline to follow-up with and without adjustment for relevant factors
Adjusted for
Muscle Unadjusted model Age + Sex + BMI Age + Sex + BMI + Leg strength
Muscle thickness
L2/L3_MF (relaxed) 0.092 (0.026, 0.211) 0.115 (0.004, 0.234) 0.172 (0.048, 0.296)*
L2/L3_MFa 0.000 (0.052, 0.051) 0.115 (0.054, 0.051) 0.176 (0.073, 0.037)
L3/L4_MF (relaxed) 0.027 (0.073, 0.127) 0.038 (0.063, 0.139) 0.054 (0.052, 0.161)
L3/L4_MFa 0.015 (0.042, 0.072) 0.017 (0.041, 0.074) 0.001 (0.062, 0.060)
L4/L5_MF (relaxed) 0.024 (0.102, 0.150) 0.050 (0.076, 0.176) 0.089 (0.045, 0.222)
L4/L5_MFa 0.003 (0.056, 0.050) 0.003 (0.049, 0.056) 0.025 (0.054, 0.059)
L5/S1_MF (relaxed) 0.048 (0.172, 0.076) 0.028 (0.152, 0.096) 0.015 (0.146, 0.117)
L5/S1_MFa 0.007 (0.052, 0.066) 0.015 (0.043, 0.073) 0.017 (0.044, 0.078)
Cross sectional area
L2_MF_CSA 0.066 (0.142, 0.009) 0.059 (0.135, 0.017) 0.060 (0.140, 0.020)
L3_MF_CSA 0.021 (0.125, 0.083) 0.016 (0.120, 0.089) 0.039 (0.069, 0.147)
L4_MF_CSA 0.063 (0.169, 0.043) 0.062 (0.168, 0.045) 0.041 (0.148, 0.067)
L5_MF_CSA 0.112 (0.246, 0.022) 0.129 (0.260, 0.003) 0.120 (0.259, 0.019)
All measures are in cm, and are reported as mean (standard error). CSA, cross sectional area; MF, multiﬁdus muscle.
aAbsolute change in muscle thickness with contraction calculated as (thickness when contracted – thickness when relaxed).
*Statistically signiﬁcant P < 0.05.
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being plausible reasons to hypothesize that vitamin D
supplementation could improve trunk muscle size, our results
suggest that increases or maintenance of muscle size or
function of older adults cannot be expected from vitamin D
supplementation alone, at least over the limited timeframe
of 1 year. In peripheral muscles, two systematic reviews
reported positive effects of vitamin D supplementation on
muscle strength in older adults with baseline 25(OH)
D < 30 nmol/L (<12 ng/mL).15,44 However, in our study of
trunk muscles, the response to supplementation did not vary
between people with moderate to severe deﬁciency 25(OH)
D (<25 nmol/L, <10 ng/mL) at baseline and those with
25(OH) D levels above this level. Thus, even in people
with this degree of deﬁciency, vitamin D supplementation
does not improve trunk muscle size or muscle function as
assessed by change in muscle thickness during submaximal
contraction.
While there is no consensus on the amount of variation in
trunk muscle size required to ascertain clinically meaningful
changes in these muscles,30 previous studies investigating
the effect of exercise programmes on trunk muscles in
people with low back pain have found interventions that
increased muscle size were associated with decreases in
pain.37,45,46 The changes in muscle sizes observed in those
studies were larger than those seen in our study, for
example, being over 5% for measures of the multiﬁdus and
transversus abdominis muscles at rest.37,45 Thus, exercise
programmes or a combination of exercise and functional
activities that target trunk muscles may be more effective
in improving these muscles than vitamin D supplementation
alone.
The effects of vitamin D supplementation on peripheral
muscle strength, mass, and power have been examined in
a systematic review and meta-analysis.15 The studies in this
review administered a wide range of vitamin D doses (as
low 300 IU/day, up to intermittent doses equivalent to
around 8600 IU/day). For muscle strength, there was a
small but statistically signiﬁcant positive effect of vitamin
D supplementation on lower limb muscle strength [19
studies in 2349 people; vitamin D dose range
400–8600 IU; standard mean difference = 0.19 (95% CI
0.05–0.34)]. However, there was no statistically signiﬁcant
effect of vitamin D supplementation neither on grip
strength (16 studies, doses 400–8600 IU/day) nor on muscle
mass (six studies, n = 538, doses 300–4000 IU/day) or
power (ﬁve studies, n = 245, doses 400–4000 IU/day). The
latter is consistent with the lack of effect on muscle size
observed in the current study, but as trunk muscle strength
and power were not measured in our study, it remains to
be determined whether vitamin D supplements affect
strength or power in trunk muscles.
Previous studies have reported improvements in measures
of functional mobility (walking test and ‘timed up and go’
test) and reduced risk of falls with vitamin D supplementation
of older adults.47,24 Although the present study did not
investigate the effect of vitamin D supplementation on falls
or functional mobility, our results suggest that changes to
these outcomes are not mediated by trunk muscle size. The
Table 6 Adverse events
Vitamin D (N = 104) Placebo (N = 113)
No. of participants (%) No. of participants (%)
Serious adverse events
Death 1 (1.0) 0 (0.0)
Malignancy 2 (1.9) 2 (1.8)
Coronary artery disease 1 (1.0) 1 (0.9)
Severe infection 0 (0.0) 1 (0.9)
Major depression 1 (1.0) 0 (0.0)
Nephrolithiasis 1 (1.0) 1 (0.9)
Hospitalization 1 (1.0) 0 (0.0)
Adverse events
Hypercalcaemia 2 (1.9) 2 (1.8)
Hyperparathyroidism 1 (1.0) 0 (0.0)
Renal 2 (1.9) 0 (0.0)
Falls 2 (1.9) 0 (0.0)
Musculoskeletal 1 (1.0) 1 (0.9)
Neurological 1 (1.0) 1 (0.9)
Gastrointestinal 1 (1.0) 3 (2.7)
Respiratory 2 (1.9) 1 (0.9)
Ocular 1 (1.0) 1 (0.9)
Infection 4 (3.9) 2 (1.8)
Cardiac arrhythmia 1 (1.0) 0 (0.0)
Chest pain 4 (3.9) 4 (3.5)
Pain 6 (5.8) 2 (1.8)
Allergy/immunology 0 (0.0) 2 (1.8)
Other eventsa 9 (8.7) 6 (5.3)
aIncluding headache, lethargy, ﬂu symptoms, and other events.
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effect of vitamin D supplementation on other aspects of
trunk muscle function such as strength cannot be ruled out
and should be the focus of future research.
Strengths and limitations
The strength of the current investigation is its design. It is a
double-blind RCT, which provides robust evidence regarding
the efﬁcacy of vitamin D supplementation for improving
trunk muscle size. Participants in this study were
community-dwelling adults with low serum 25(OH) D. This
is the sub-population most likely to beneﬁt from vitamin D
supplementation.
It has limitations nevertheless. While the use of random
allocation helps to reduce the possibility of imbalance be-
tween the treatment arms, in this case randomization did
not produce exact balance. However, we collected informa-
tion that made it possible to adjust for these factors, and
the results of the adjusted analyses did not alter the overall
conclusions of the study. While the study sample was on av-
erage only mildly deﬁcient, there was no interaction between
treatment response and vitamin D status at baseline, suggest-
ing that the results are generalizable to both mildly and
moderately deﬁcient people. While our sample size was mod-
est, we powered the study appropriately to detect treatment
effects that were likely to be clinically meaningful based on
existing literature.37,45,48 We are therefore unlikely to have
failed to detect any clinically important treatment effects.
The majority of participants were either overweight or obese,
which could have inﬂuenced their serum 25(OH) D response
to supplementation. However, participants with high BMI still
achieved large increases in 25(OH) D and a much higher pro-
portion of these participants reached levels ≥75 nmol/L
(≥30 ng/mL) than in the placebo group. Furthermore, there
was no interaction between treatment response and BMI,
so the impact of being an obese population on our results
was minimal. The lack of any interaction also suggests that
our result are generalizable to people with osteoarthritis
who are of normal weight. It is possible that mobility restric-
tions from knee osteoarthritis may have affected participants’
ability to improve trunk muscle size. Nevertheless, levels of
knee pain in the study were relatively low, functional
limitations were modest, and physical activity levels were
reasonable, which makes this scenario unlikely. We used a
DiaSorin immunoassay method to measure serum 25(OH) D,
rather than mass spectrometry which is considered the gold
standard. However, mass spectrometry is not readily avail-
able in clinical practice, which would affect translation into
practice, and a recent study found that the DiaSorin immuno-
assay achieved acceptable performance when compared with
mass spectrometry.49 Our only measure of muscle function
was change in muscle thickness with contraction, so we
cannot rule out effects of vitamin D supplementation on
other aspects of muscle function such as strength, power,
physical function, or falls.
Conclusions
There is no evidence that a monthly dose of 50 000 IU of vi-
tamin D3 alone has an effect on the size or ability to contract
trunk muscles of independent community-dwelling older
adults with symptomatic knee osteoarthritis and low serum
25(OH) D levels regardless of BMI status or degree of vitamin
D deﬁciency. An effect of vitamin D supplementation on
other aspects of trunk muscle function such as strength,
power, or physical function cannot be ruled out.
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